AbbVie has revealed that 17 AbbVie-sponsored abstracts, featuring fresh insights from its inflammatory bowel disease (IBD) portfolio, have been accepted for showcase at the 19th Congress of European Crohn’s and Colitis Organisation (ECCO) in Stockholm, Sweden from February 21-24.
Included in the accepted research are nine oral presentations and eight posters, covering risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn’s disease (CD) and ulcerative colitis (UC).
“Despite ongoing advancements, numerous IBD patients still grapple with its debilitating effects,” remarked Sofie Berg, Pharm.D, Ph.D., therapeutic area head, international immunology, International Medical Affairs, AbbVie. “Our array of data at this year’s congress underscores our unwavering commitment to advancing IBD care standards, integrating endoscopic outcomes like mucosal healing as pivotal trial endpoints.”
Highlighted data presentations include:
Post-hoc analyses from the SEQUENCE trial comparing risankizumab versus ustekinumab in CD Primary safety and efficacy maintenance findings from the COMMAND Phase 3 study of risankizumab in adult UC patients Post-hoc analyses of risankizumab Phase 2b/3 trials in UC patients Long-term efficacy and safety insights from Phase 3 maintenance studies across the gastroenterology portfolio for CD Retreatment with upadacitinib in UC patients
Risankizumab remains unapproved for UC treatment.
SKYRIZI® (risankizumab) is developed and commercialized globally through a partnership between Boehringer Ingelheim and AbbVie, with AbbVie leading the effort.
